Cardiff Oncology Q2: Going Concern Warning, $10.1M Raise, and NMS License Fight
CRDF sits 39% above its 52-week low of $0.757.
Summary
Cardiff Oncology's Q2 2026 filing reiterates a going concern warning, discloses a $10.1 million post-quarter financing, and provides an update on the existential license dispute with Nerviano Medical Sciences over onvansertib.
Key Events · Earnings and Guidance · CRDF
-
Going Concern Warning Reiterated
Cash, cash equivalents, and short-term investments totaled $34.5 million as of June 30, 2026, which management states is insufficient to fund operations for the next 12 months. Substantial doubt exists about the company's ability to continue as a going concern.
-
$10.1M Post-Quarter Financing
On July 14, 2026, Cardiff closed a registered direct offering of 8.57 million shares with accompanying warrants at $1.05 per share, plus 721,649 shares to insiders at $1.455 per share, raising gross proceeds of $10.1 million. The financing extends the cash runway into Q3 2027.
-
Existential License Dispute with NMS
Nerviano Medical Sciences (NMS) is attempting to terminate the license agreement for onvansertib, alleging material breach. Cardiff has filed a lawsuit and a motion for preliminary injunction to block the termination. The motion is fully briefed and awaiting a court decision. If NMS prevails, Cardiff loses rights to its only clinical asset.
-
Phase 2 Data and Phase 3 Plans
The Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC showed a 72.2% ORR for onvansertib 30 mg + FOLFIRI/bev vs. 42.1% for standard of care. The company has designed a registrational Phase 3 trial (CRDF-005) and completed an End-of-Phase 2 meeting with the FDA.
Analysis · CRDF · Life Sciences
Cardiff Oncology's Q2 report confirms a going concern warning with only $34.5 million in cash — not enough to fund operations for the next 12 months. The company closed a $10.1 million registered direct offering after the quarter ended, but that only extends the runway into Q3 2027. The existential threat is the ongoing litigation with Nerviano Medical Sciences, which is attempting to terminate the license for onvansertib, the company's only clinical asset. If NMS prevails, Cardiff loses its entire pipeline. The combination of a cash crunch and a license dispute that could wipe out the company's lead drug makes this a critical update.
At the time of this filing, CRDF was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.9M. The 52-week trading range was $0.76 to $3.31. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.